Imatinib Hcs

Imatinib, the active ingredient in Imatinib Hcs, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers and solid tumours, specifically targeting malignant cells that express BCR‑ABL, c‑KIT or PDGFR.

GNH USA supplies Imatinib Hcs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across multiple regions. Our global network facilitates timely access to essential oncology medicines, supporting patient care in both established and emerging markets.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing therapeutic benefit in several oncologic indications.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation, achieves disease control and prolongs survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): targets BCR‑ABL‑positive blasts to induce remission and improve outcomes. - Gastrointestinal stromal tumor (GIST): blocks c‑KIT signaling, inhibiting tumor growth and disease progression.

Imatinib may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Edema - Muscle cramps - Fatigue

Serious or Rare Side Effects: - Hepatotoxicity - Severe neutropenia - Cardiac failure - Pulmonary hypertension

Patients receiving Imatinib should be monitored closely for safety and tolerability.

- Monitor blood counts: perform regular complete blood count testing to detect cytopenias. - Assess liver function: check hepatic enzymes periodically for signs of hepatotoxicity. - Evaluate cardiac status: perform baseline and periodic cardiac assessment in patients with risk factors. - Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs. - Use caution in pregnancy: potential risks are unknown; consider alternative therapy. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Imatinib can interact with several medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - CYP2C8 substrates (e.g., paclitaxel): may require dose adjustment. - Diuretics (e.g., furosemide): may increase risk of hypokalemia when combined with imatinib. - Live attenuated vaccines: should be used with caution due to potential immunomodulatory effects.